Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Chuck

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|February 12, 2010
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trialAndrew R Zolopa, Daniel S Berger, Harry Lampiris, et al.
American Heart Journal|September 1, 1981
Hemodynamic effects of prazosin in chronic heart failureW W Parmley, K Chatterjee, S Arnold, et al.
AIDS (London, England)|August 4, 2011
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, Calvin Cohen, Joseph Gathe, et al.
The Lancet. Infectious Diseases|October 22, 2011
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
The Pediatric Infectious Disease Journal|March 12, 2015
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppressionXavier Saez-Llorens, Elizabeth Castaño, Mobeen Rathore, et al.
Gastroenterology|November 8, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescentsMarinella Della Negra, Aroldo Prohmann de Carvalho, Maria Zilda de Aquino, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Infectious Diseases|February 12, 2010
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trialAndrew R Zolopa, Daniel S Berger, Harry Lampiris, et al.
American Heart Journal|September 1, 1981
Hemodynamic effects of prazosin in chronic heart failureW W Parmley, K Chatterjee, S Arnold, et al.
AIDS (London, England)|August 4, 2011
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, Calvin Cohen, Joseph Gathe, et al.
The Lancet. Infectious Diseases|October 22, 2011
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
The Pediatric Infectious Disease Journal|March 12, 2015
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppressionXavier Saez-Llorens, Elizabeth Castaño, Mobeen Rathore, et al.
Gastroenterology|November 8, 2006
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
The Pediatric Infectious Disease Journal|February 4, 2012
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescentsMarinella Della Negra, Aroldo Prohmann de Carvalho, Maria Zilda de Aquino, et al.
Pageof 3